Skip to main content

REVIEW article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1478703

Enhancing Broadly Neutralising Antibody Suppression of HIV by Immune Modulation and Vaccination

Provisionally accepted
Carla Nel Carla Nel 1John Frater John Frater 1,2*
  • 1 Nuffield Dept of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom
  • 2 NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

The final, formatted version of the article will be published soon.

    Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection. Emerging data are encouraging, but suggest that combinations of bNAbs with other immunomodulatory agents may be needed to induce and sustain long-term viral control. As a result, a number of clinical trials are currently underway exploring these combinations. If successful, the impact for the millions of people living with HIV could be substantial. Here, we review the background to the use of bNAbs in the search for an HIV cure and how different adjunctive agents might be used together to enhance their efficacy.

    Keywords: HIV, Therapeutics, broadly neutralising antibodies, Latency-reversing agents, Immune modulators, Vaccines, Cure

    Received: 10 Aug 2024; Accepted: 17 Oct 2024.

    Copyright: © 2024 Nel and Frater. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: John Frater, Nuffield Dept of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, United Kingdom

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.